Streamlined selection of cancer antigens for vaccine development through integrative multi-omics and high-content cell imaging

• Published in: Scientific reports 2020-04, Vol.10 (1), p.5885-5885, Article 5885
• Main Authors: Han, Ki-Cheol, Park, Daechan, Ju, Shinyeong, Lee, Young Eun, Heo, Sun-Hee, Kim, Young-Ae, Lee, Ji Eun, Lee, Yuna, Park, Kyong Hwa, Park, Se-Ho, Lee, Hee Jin, Lee, Cheolju, Jang, Mihue
• Format: Article
• Language: English
• Subjects: 631/114; 631/1647; 631/1647/2067; 631/1647/2163; 631/1647/48; 631/1647/664; 631/250; 631/45; 631/67; 692/4028/67; Antigen (tumor-associated); Antigens; Antigens, Neoplasm - immunology; Breast cancer; Cancer; Cancer vaccines; Cancer Vaccines - immunology; Computer applications; Cytotoxicity; Epitopes; Gas Chromatography-Mass Spectrometry; High-Throughput Screening Assays; Histocompatibility antigen HLA; HLA Antigens - immunology; Humanities and Social Sciences; Humans; Immunogenicity; Immunoreactivity; Lymphocytes; Lymphocytes T; multidisciplinary; Peptides; Proteomics - methods; Receptors, Antigen, T-Cell - immunology; Science; Science (multidisciplinary); Triple Negative Breast Neoplasms - immunology; Vaccine development; Vaccines
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-62244-z

Identification of tumor antigens that induce cytotoxic T lymphocytes (CTLs) is crucial for cancer-vaccine development. Despite their predictive ability, current algorithmic approaches and human leukocyte antigen (HLA)-peptidomic analysis allow limited selectivity. Here, we optimized a method to rapidly screen and identify highly immunogenic epitopes that trigger CTL responses. We used a combined application of this method involving immune-specific signature analysis and HLA-associated peptidomics using samples from six patients with triple-negative breast cancer (TNBC) in order to select immunogenic HLA epitopes for in vitro testing. Additionally, we applied high-throughput imaging at the single-cell level in order to confirm the immunoreactivity of the selected peptides. The results indicated that this method enabled identification of promising CTL peptides capable of inducing antitumor immunity. This platform combining high-resolution computational analysis, HLA-peptidomics, and high-throughput immunogenicity testing allowed rapid and robust identification of highly immunogenic epitopes and represents a powerful technique for cancer-vaccine development.